New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 12, 2014
20:04 EDTICPTIntercept reports additional positive data from POISE trial at EASL
Intercept Pharmaceuticals announced efficacy and safety results from the Phase 3 POISE trial of obeticholic acid, OCA, for the treatment of primary biliary cirrhosis, PBC, to be presented in a late-breaker session at the International Liver Congress of the European Association for the Study of the Liver, EASL. OCA, Intercept's lead product candidate, is a bile acid analog and first-in-class agonist of the farnesoid X receptor, FXR in development for PBC, nonalcoholic steatohepatitis, NASH, and other liver and intestinal diseases. As previously reported, the POISE trial met its primary endpoint with high statistical significance, demonstrating OCA's efficacy on a composite liver biochemical endpoint which has been shown to strongly correlate with improved clinical outcomes. The proportion of patients meeting the POISE primary endpoint was: 10% in the placebo group, 47% in the 10 mg OCA group and 46% in the 5-10 mg OCA group. New data in the presentation show that OCA treated patients achieved a highly statistically significant reduction in alkaline phosphatase, ALP, as early as two weeks, with a peak effect achieved by six months.Pruritus, generally mild to moderate, was the most frequently reported adverse event in the POISE trial. However, only 1% of the patients in the OCA 5-10 mg titration group discontinued therapy due to pruritus after moving up to the 10 mg dose, as compared to seven, 10%, of the patients in the 10 mg OCA group. Additional data presented show that the incidence and severity of OCA related pruritus diminishes with time on therapy. Specifically, pruritus scores were no different from placebo in both OCA treatment groups during the second half of the trial.
News For ICPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 14, 2014
15:22 EDTICPTIntercept CEO says company 'very well-positioned' in terms of balance sheet
Subscribe for More Information
November 12, 2014
12:00 EDTICPTKOLs say 'remains to be seen' if OCA can get accelerated approval, says Leerink
Subscribe for More Information
11:55 EDTICPTIntercept not part of talks with journals, says Deutsche Bank
Subscribe for More Information
November 11, 2014
12:00 EDTICPTIntercept results said to be rejected by New England Journal, Bloomberg says
Subscribe for More Information
November 10, 2014
08:36 EDTICPTIntercept price target lowered to $125 from $172 at FBR Capital
FBR Capital lowered its price target for Intercept shares to $125 saying its talks with experts and cardiologists indicate the company's OCA drug is unlikely to be a "silver bullet" for the treatment of nonalcoholic steatohepatitis. FBR notes that while OCA appears to improve the liver, the drug worsens many of the other derangements like lipid and glucose homeostasis. FBR decreased the probability of success in NASH to 55% from 60%, and lowered its peak OCA sales estimate to $5.2B. It keeps an Underperform rating on Intercept shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use